A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult
patients with relapsed or refractory CLL, NHL or MM. Patients will be enrolled into the study
in sequential dose cohorts.
Patients will be administered a single IV infusion of GS 9219 on Day 1 of a 21 day cycle and
may receive a total of six treatment cycles based on toxicities and response. Patients who
demonstrate disease progression will be discontinued from the study. Patients who, at the
completion of six treatment cycles, tolerate treatment and show evidence of disease control
(response or stabilization) will be eligible to continue receiving treatment at the same
dose.